Bayer

(IN BRIEF) The Mobility House has restructured into four specialized business units—The Mobility House Energy, Solutions, Charging, and North America—to better serve the evolving energy and mobility markets. This reorganization aims to enhance flexibility and support the company’s goal of … Read the full press release →

(IN BRIEF) Bayer and Evotec have updated their strategic collaboration to focus on developing precision treatments for cardiovascular diseases (CVDs). Leveraging Evotec’s expertise in disease modelling using human induced pluripotent stem cells (iPSCs), the collaboration aims to identify and validate … Read the full press release →

(IN BRIEF) Unilever has announced the appointment of Heiko Schipper as President of the Nutrition Business Group, effective May 1, 2024. Heiko, currently serving as President of Bayer Consumer Health, brings extensive experience and a successful track record in the … Read the full press release →

(IN BRIEF) Japan’s Ministry of Health, Labor and Welfare (MHLW) has authorized the marketing and manufacturing of Dupixent® (dupilumab) for treating chronic spontaneous urticaria (CSU) in patients aged 12 years and older. This approval marks a significant milestone as Japan … Read the full press release →

(IN BRIEF) Covestro has inaugurated a groundbreaking pilot plant at its Leverkusen site, heralding a significant leap in chemical production. This innovative facility is set to produce aniline—a crucial chemical component—solely from plant biomass, departing from traditional petroleum-based methods. Aniline … Read the full press release →

(IN BRIEF) The U.S. Food and Drug Administration (FDA) has granted approval for Dupixent® (dupilumab) to treat pediatric patients aged 1 to 11 years, weighing at least 15 kg, who suffer from eosinophilic esophagitis (EoE). Dupixent is now the first … Read the full press release →

(IN BRIEF) In a significant development, the second investigational Phase 3 trial of Dupixent® (dupilumab) for chronic obstructive pulmonary disease (COPD), known as NOTUS, has demonstrated promising results. The trial found that Dupixent reduced COPD exacerbations by 34% compared to … Read the full press release →

(IN BRIEF) German materials manufacturer Covestro has announced a global partnership with Chinese automotive trim company Xinquan Automotive during the China International Import Expo in Shanghai. This strategic alliance aims to strengthen Xinquan’s presence in North America, Europe, and ASEAN … Read the full press release →

(IN BRIEF) Bayer has invested $250 million in a new cell therapy production plant in Berkeley, California, USA. This investment aims to support the production of materials for clinical trials and potential commercial launches of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), an … Read the full press release →